Curated News
By: NewsRamp Editorial Staff
June 11, 2026

SureNano Science Initiates Key Preclinical Phase for Obesity Drug GEP-44

Discuss on LinkedIn Discuss on X, formerly Twitter Discuss on Substack Discuss on Telegram participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • SureNano Science initiates FDA-aligned GLP tox studies for GEP-44, aiming to lead in next-gen GLP-1 obesity market.
  • GEP-44, a multi-receptor peptide, enters GLP toxicology and pharmacology program to support IND application with LabCorp.
  • SureNano's GEP-44 targets obesity and diabetes, offering improved tolerability and potential non-injectable delivery for better patient outcomes.
  • SureNano licenses GEP-44 from Syracuse University, a patented peptide designed for non-injectable obesity treatment.

Impact - Why it Matters

This news matters because obesity and type 2 diabetes are global epidemics affecting millions, and current treatments often have limitations like tolerability issues or require injections. SureNano's GEP-44, a next-generation GLP-1 therapy, aims to offer improved tolerability and potential non-injectable delivery, which could expand access and adherence. The initiation of FDA-aligned preclinical studies brings this promising candidate closer to human trials, offering hope for more effective and patient-friendly treatments. For investors, it signals progress in a high-growth market.

Summary

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, is making significant strides in the fight against obesity and type 2 diabetes. The company recently announced the initiation of a key phase of preclinical development for its lead drug candidate GEP-44, a multi-receptor peptide designed to address these metabolic disorders. This phase involves a Good Laboratory Practice (GLP) toxicology and pharmacology program aligned with U.S. Food and Drug Administration (FDA) requirements, a critical step before filing an Investigational New Drug (IND) application and proceeding to first-in-human clinical trials. The program is being conducted in partnership with LabCorp, a globally renowned contract research organization (CRO), ensuring the highest regulatory standards. Dr. Nihar Pandey, Chief Scientific Officer at SureNano, emphasized that this milestone moves the company firmly towards clinical-stage evaluation, with plans to launch a Phase I clinical trial in Australia.

SureNano Science has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company that developed GEP-44, a patented peptide offering improved tolerability and potential for non-injectable delivery. This positions SureNano as an agile entrant in the rapidly expanding GLP-1 market, which is dominated by drugs like Ozempic and Wegovy. The company's innovative approach, based on second-generation incretin therapy, could provide a more tolerable and convenient treatment option for patients. In addition to its pharmaceutical focus, SureNano Science also sells and distributes the SureNano™ surfactant, a food-grade compound used in high-performance nanoemulsions for various industries. The company has exclusive distribution rights for this product in Canada, Oklahoma, and Colorado.

Investors can stay updated on SureNano Science's progress through its newsroom at https://ibn.fm/SURNF. The full article detailing these developments is available at https://ibn.fm/78hI3. SureNano Science is traded on the Canadian Securities Exchange under the ticker SURE and on the OTCQB under SURNF. The company's dual focus on innovative therapeutics and specialized surfactants underscores its commitment to addressing major health challenges while leveraging its technological expertise.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, SureNano Science Initiates Key Preclinical Phase for Obesity Drug GEP-44

blockchain registration record for this content.